Ekso Bionics Holdings Inc (NASDAQ:EKSO) has a beta value of 1.47 and has seen 33.3 million shares traded in the recent trading session. The company, currently valued at $21.37M, closed the recent trade at $0.83 per share which meant it gained $0.1 on the day or 13.48% during that session. The EKSO stock price is -265.06% off its 52-week high price of $3.03 and 39.76% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.46 million shares traded. The 3-month trading volume is 161.42K shares.
The consensus among analysts is that Ekso Bionics Holdings Inc (EKSO) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Ekso Bionics Holdings Inc (NASDAQ:EKSO) trade information
Sporting 13.48% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the EKSO stock price touched $0.83 or saw a rise of 16.86%. Year-to-date, Ekso Bionics Holdings Inc shares have moved 35.80%, while the 5-day performance has seen it change 27.64%. Over the past 30 days, the shares of Ekso Bionics Holdings Inc (NASDAQ:EKSO) have changed 18.51%. Short interest in the company has seen 0.12 million shares shorted with days to cover at 1.07.
Wall Street analysts have a consensus price target for the stock at $2, which means that the shares’ value could jump 58.5% from the levels at last check today. The projected low price target is $2.0 while the price target rests at a high of $2.0. In that case, then, we find that the latest price level in today’s session is -140.96% off the targeted high while a plunge would see the stock gain -140.96% from the levels at last check today.
Ekso Bionics Holdings Inc (EKSO) estimates and forecasts
Figures show that Ekso Bionics Holdings Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -24.69% over the past 6 months, with this year growth rate of 56.36%, compared to 15.20% for the industry. Revenue growth from the last financial year stood is estimated to be -0.87%.
2 analysts offering their estimates for the company have set an average revenue estimate of 5.3M for the current quarter. 2 have an estimated revenue figure of 5.05M for the next ending quarter. Year-ago sales stood 4.85M and 3.76M respectively for this quarter and the next, and analysts expect sales will grow by 9.40% for the current quarter and -0.87% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 30.19% over the past 5 years.
EKSO Dividends
Ekso Bionics Holdings Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Ekso Bionics Holdings Inc (NASDAQ:EKSO)’s Major holders
Insiders own 7.91% of the company shares, while shares held by institutions stand at 25.25% with a share float percentage of 27.42%. Investors are also buoyed by the number of investors in a company, with Ekso Bionics Holdings Inc having a total of 30.0 institutions that hold shares in the company. The top two institutional holders are KENT LAKE CAPITAL LLC with over 0.7 million shares worth more than $0.73 million. As of 2024-06-30, KENT LAKE CAPITAL LLC held 3.9959% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 0.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.63 million and represent 3.4125% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 1.82% shares in the company for having 400.89 shares of worth $0.32 million while later fund manager owns 179.46 shares of worth $0.14 million as of Sep 30, 2024, which makes it owner of about 0.82% of company’s outstanding stock.
